Metocure-T 25 Tablet ER is a combination antihypertensive medication containing Telmisartan 40 mg and Metoprolol Succinate 25 mg, formulated for extended release. Telmisartan, an angiotensin II receptor blocker (ARB), selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, which leads to decreased blood pressure. Metoprolol Succinate, a cardioselective beta-1 adrenergic receptor blocker, reduces heart rate, myocardial contractility, and cardiac output, contributing to its antihypertensive effect. The extended-release formulation ensures a sustained therapeutic effect, improving patient compliance by allowing once-daily dosing. Metocure-T 25 is indicated for the management of essential hypertension, providing effective blood pressure control and reducing the risk of cardiovascular events such as stroke and myocardial infarction. It may also be beneficial in patients with concomitant conditions like ischemic heart disease or heart failure, where beta-blockade is advantageous. Caution is advised in patients with bradycardia, severe hepatic or renal impairment, and asthma or other bronchospastic conditions. Common adverse effects include dizziness, fatigue, and hypotension. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy to ensure safety and efficacy.